Želite vložiti pritožbo zoper institucijo ali organ EU?

Iskanje po preiskavah

Primer
Datumski razpon
Ključne besede
Iskanje s starimi ključnimi besedami (pred 2016)

Prikaz rezultatov 1–20 od 146

Decision on how the European Commission dealt with the impact of the COVID-19 crisis on the work of researchers participating in the EU-funded Marie Skłodowska-Curie Actions (joint cases 1242/2020/SF and 1380/2020/SF)

Četrtek | 01 julij 2021

The complaints concerned the European Commission’s decision not to extend funding for those carrying out research under the EU-funded Marie Skłodowska-Curie Action Programme (MSCA) following the impact of the COVID-19 crisis on the work of researchers. The complainants considered that the measures the Commission put in place to support MSCA researchers during the COVID-19 crisis were insufficient, as they would not enable them to continue their work.

The Ombudsman opened an inquiry into how the Commission communicated with project partners that received grants under the MSCA, and the researchers carrying out the work for those project partners, about the measures they could take to address the impact of the COVID-19 crisis on their projects.

During the inquiry, the Ombudsman shared her preliminary findings with the Commission. In particular, the inquiry showed that, overall, the Commission had taken appropriate action to communicate the measures that could be taken to support researchers according to the applicable rules. However, as no solution had been found for the complainants, she urged the Commission to explore whether additional funding could exceptionally be awarded to the complainants and researchers in similarly difficult situations.

The Commission broadly accepted the Ombudsman’s preliminary findings but reiterated that, due to legal and financial constraints, it cannot provide any exceptional funding.

The Ombudsman appreciates the difficult situation faced by many MSCA researchers due to the COVID-19 crisis. At the same time, she acknowledges the Commission’s commitment to find solutions within the applicable rules for those researchers impacted. While it is regrettable that a solution could not be found for the complainants and researchers in similar situations, the Ombudsman closed the case as further inquiries would not result in a more satisfactory outcome for the complainants. However, she made two suggestions for improvement.

Odločba v zadevi 1525/2020/MIG o tem, kako je Evropska komisija obravnavala zahtevek za dostop javnosti do dokumentov v zvezi s sestanki med njeno predsednico in predstavniki industrije, vključno s podjetjem, ki je razvijalo cepivo proti covidu-19

Petek | 19 marec 2021

Zadeva se je nanašala na zahtevek za dostop javnosti do vseh dokumentov, ki so se nanašali na pet videokonferenc predsednice Evropske komisije s predstavniki industrije spomladi 2020, vključno s sestankom z biofarmacevtskim podjetjem, ki je razvijalo cepivo proti covidu-19. Pritožnik je izrazil zaskrbljenost, ker Komisija ni opredelila vseh dokumentov iz njegovega zahtevka in mu je omogočila dostop samo do dela enega od dvanajstih dokumentov, ki jih je opredelila, in sicer do predstavitve, ki jo je pripravilo zadevno biofarmacevtsko podjetje.

Med preiskavo varuhinje človekovih pravic je Komisija opredelila tri dodatne dokumente, do katerih je omogočila širok dostop. Varuhinja človekovih pravic je sicer izrazila obžalovanje, da Komisija teh dokumentov sprva ni opredelila kot dokumente, na katere se nanaša pritožnikov zahtevek, vendar zdaj zadevo šteje za rešeno.

Varuhinja človekovih pravic je po pregledu zadevne predstavitve menila, da obstaja prevladujoči javni interes za razkritje, in kot rešitev predlagala, naj Komisija omogoči dostop širši javnosti. Komisija te rešitve ni sprejela, pri čemer je vztrajala, da so zadevne informacije poslovno občutljive, da se zadevno podjetje ne strinja z njihovim razkritjem in da ni prevladujočega javnega interesa.

Varuhinja človekovih pravic je odločitev Komisije sicer obžalovala, vendar je razumela, da Komisija zaradi nasprotovanja podjetja verjetno ne bo razkrila informacij. Ugotovila je tudi, da si Komisija od takrat bolj prizadeva za zagotavljanje informacij o pogajanjih s proizvajalci cepiv. Varuhinja človekovih pravic je zadevo zaključila in Komisijo pozvala, naj zagotovi, da bodo zahteve glede preglednosti sestavni del sedanjih in prihodnjih pogajanj s podjetji, kadar gre za pomembne javne interese.